12:00 AM
 | 
Aug 03, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Intuniv guanfacine extended release regulatory update

FDA issued a complete response letter for Intuniv guanfacine extended release to treat ADHD in children and adolescents ages 6-17. Shire said it was unable to agree with...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >